naldemedine (Rizmoic®) is accepted for use within NHSScotland

It has been approved for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative. It has been reported to significantly improve spontaneous bowel movement response rate in patients with OIC vs. placebo.


Scottish Medicines Consortium